David Lucas Discusses the Bromodomain Inhibitor OTX015

David Lucas, PhD
Published: Monday, Apr 07, 2014

David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.

Lucas says OTX015 is a fairly new agent in the field of hematologic malignancies that targets BET bromodomain proteins 2, 3, and 4 (BRD2/3/4). There have been no published manuscripts for OTX015, but the agent’s promising activity in hematologic malignancies has been documented in various meeting abstracts.

Targeting BRD2/3/4 might give the agent a broader inhibition of certain types of gene families compared to agents that only target BRD4, for example. Lucus says OTX015 is an interesting molecule that needs to be studied more closely to understand what gene families, in addition to c-MYC, it inhibits.

David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.

Lucas says OTX015 is a fairly new agent in the field of hematologic malignancies that targets BET bromodomain proteins 2, 3, and 4 (BRD2/3/4). There have been no published manuscripts for OTX015, but the agent’s promising activity in hematologic malignancies has been documented in various meeting abstracts.

Targeting BRD2/3/4 might give the agent a broader inhibition of certain types of gene families compared to agents that only target BRD4, for example. Lucus says OTX015 is an interesting molecule that needs to be studied more closely to understand what gene families, in addition to c-MYC, it inhibits.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Publication Bottom Border
Border Publication
x